The toxicity of 5-azadC limits its clinical application, but combining it with histone deacetylase inhibitors like sodium butyrate has shown synergistic effects in FXS lymphoblastoid cell lines, leading to more effective restoration of FMR1 gene activity. The gene discussed is FMR1; the disease is fragile X syndrome.